Duboom™ Platform
Creative Biolabs has already established an advanced dual ADCC/CDC⁺ enhanced antibody platform—Duboom™,
for the production of ADCC/CDC⁺ products. The Duboom™ platform is a integration of the Afuco™ platform
with the Crea-Tag™ technology platform. The finished product, dual ADCC/CDC⁺ antibody, gives a
successful combination—fucose depletion on Fc-linked oligosaccharides for ADCC enhanced modification
and Crea-Tag™ protein-based complement modification to enhance CDC.
Mechanism of action (MOA) of the combination:
-
Afuco™ platform is under development because non-fucosylated modified antibodies exhibit
significant ADCC enhancing effects.
-
Crea-Tag™ protein as a fusion protein, when coexpressing with other antibody, can displace the
complement factor H (CFH) on tumor cells and activate complement-mediated lysis.
Fig.1 Duboom™ platform.
Crosstype™ Platform
In vitro and animal experiments have shown that IgA exerts a more efficient and stronger
cell-killing effect than IgG1 through the FcαRI receptor on the surface of effector cells. From this,
Creative Biolabs proposes a unique tandem IgG1 / IgA2 antibody that can retain IgGl FcγR binding and
FcRn mediated serum persistence with enhanced cytotoxicity.
Glyco- and Fc Protein Dual Engineering
CDC-optimized amino acid exchange-induced Fc variants, when working together with glycoengineered dual
engineered variants, show improved NK cell-mediated ADCC and CDC activity. Creative Biolabs’ scientists
have developed combined approaches based on these latest research and findings. We are committed to
combining our expertise with your mastery to achieve great success.
Feature of dual ADCC/CDC platform
Creative Biolabs’ dual ADCC/CDC platform creates opportunities to enhance the intrinsic killing
power of therapeutic antibodies:
-
Suitable for multiple antibodies against different targets
-
Inspiring potential for new or improved treatments for a variety of indications
-
Can be combined with other antibody technologies for maximum effect
For more details about our Dual ADCC/CDC Enhancement Technology service, please do not hesitate to contact us.
References
-
Cottignies-Calamarte, Andréa, Daniela Tudor, and Morgane Bomsel. "Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA." Frontiers in Immunology 14 (2023): 1037033.
under Open Access License CC BY 4.0 The original image was modified by extracting and using a part.
-
Phelps, Meredith, and Alejandro Benjamin Balazs. "Contribution to HIV prevention and treatment by antibody-mediated effector function and advances in broadly neutralizing antibody delivery by vectored immunoprophylaxis." Frontiers in Immunology 12 (2021): 734304.
under Open Access License CC BY 4.0 The original image was modified by extracting and using a part, and certain words from this image were hidden.
